Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
235 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (3)

Medical Condition

  • Show all (89)
  • Autoimmune Disorders (1)
  • Blood Disorders (3)
  • Bone & Muscle (1)
  • Cancer (18)
    • Breast Cancer (1)
    • (-) Gynecologic Cancer (2)
    • Head and Neck Cancer (1)
    • Leukemia (2)
    • Lung Cancer (2)
    • Multiple Myeloma (2)
    • Pancreatic Cancer (1)
    • Solid Tumors (2)
    • Uveal Melanoma (2)
  • COVID-19 (Coronavirus) (4)
  • Diabetes (2)
  • Endocrine & Metabolic Disease (3)
  • Hair and Skin Disorders (1)
  • Healthy Volunteers (12)
  • Heart Disease (17)
  • (-) Kidney Disease (1)
  • Liver Disease (2)
  • Lung Disease (2)
  • Neurological Disorders (3)
  • Nutrition (2)
  • Obesity (2)
  • Obstetrics & Gynecology (3)
  • Pediatrics (7)
  • Surgery (2)
  • Transplant (3)
Displaying 1 - 3 of 3

A study for patients with autosomal dominant polycystic kidney disease (ADPKD) using study drug Tolvaptan

Condition: Kidney Disease
Investigator: Jai Radhakrishnan, MD
Status: Closed
This study is for patients with autosomal dominant polycystic kidney disease (ADPKD). The purpose of this study is to test the effectiveness of a study drug called tolvaptan. Tolvaptan continues to be studied in this trial as a possible treatment for ADPKD. ADPKD is a disease that causes kidney cysts (cyst are like fluid-filled balloons), worsening kidney…
Read More

Study of SL-172154 in Combination with PLD or MIRV in Patients with Ovarian Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
The purpose of this research study is to test the safety and determine the highest tolerable dose of SL-172154 (study drug) that can be given with Pegylated Liposomal Doxorubicin (PLD) or Mirvetuximab Soravtansine (MIRV). Another purpose of this study is to understand if SL-127154 and PLD or MIRV is effective in managing…
Read More

Study of Upifitamab Rilsodotin (XMT-1536) in Patients with Recurrent Ovarian Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
XMT-1536 (upifitamab rilsodotin) is a targeted therapy, which means that it is directed specifically at a tumor. It is a type of antibody-drug conjugate; this means it has 2 parts that are joined together into one drug. The first part is an antibody that binds to NaPi2b (sodium-dependent phosphate transporter), a protein on the surface of the cells of your…
Read More
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Terms of Use Privacy Policy ©2026 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science